← Cancer trial database
Trial
Non-small cell lung cancer

Phase 1/2 NHT102 inhaled azacitidine DNA hypomethylating agent (DNMT inhibitor) in NSCLC

Trial status

Registered, Not Yet Recruiting

Status as of

Got an update?
Trial ID
NCT07864584 on ClinicalTrials.gov
Cancer type
Non-Small Cell Lung Cancer (NSCLC)
Stage of research
First-in-human
Location
Canton, OH
Published in
New in Oncology - Nov 12, 2026

NHT102-001 is an open-label, multi-center Phase 1/2 trial testing NHT102, an inhaled dry-powder formulation of azacitidine delivered via Nob Hill Therapeutics’ investigational DryNeb device. Azacitidine is a DNA methyltransferase (DNMT) inhibitor (a hypomethylating agent) intended to reprogram tumor biology epigenetically; here, the commercial/scientific bet is that lung-targeted delivery can drive local exposure in the chest while limiting systemic toxicity versus conventional parenteral dosing. Part 1 uses a standard 3+3 dose-escalation (target lung dose range ~7–42 mg per treatment day) to define dose-limiting toxicities and a tolerated dose, then carries forward up to two dose levels with preliminary activity. In Part 2, patients are randomly assigned 1:1 between two selected doses (Simon two-stage–style activity assessment) to choose a recommended Phase 2 dose, and Part 3 expands at that dose for a clearer safety/PK/PD and antitumor signal. The population is advanced, recurrent/persistent stage I–III NSCLC confined to lung/chest region after prior therapy (after prior curative-intent therapy, with no further curative option); management depends on prior therapy and remaining systemic options, so this explores a distinctly regional drug-device approach in patients without another curative option.

More in non-small cell lung cancer

See all entries in non-small cell lung cancer →